Matches in Nanopublications for { ?s ?p "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP666308.RAZ40NuUkS9aenhGy6TNRbbxKsCzvFGs9DzPiaQQ3lUCE130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666308.RAZ40NuUkS9aenhGy6TNRbbxKsCzvFGs9DzPiaQQ3lUCE130_provenance.
- NP717056.RAeDsydUSx7qIH4DqNuXI8epZB8UYJznAu9qIIKKQ9Oio130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP717056.RAeDsydUSx7qIH4DqNuXI8epZB8UYJznAu9qIIKKQ9Oio130_provenance.
- NP523996.RAvKvIT7Ad7WAQpMq8AlAjha-732L_99DuB2V8UOTc3YE130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP523996.RAvKvIT7Ad7WAQpMq8AlAjha-732L_99DuB2V8UOTc3YE130_provenance.
- NP524111.RAqIB6_S0f6cmJRzqone1AI4Csc55WPp1VrE6cXvv3648130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524111.RAqIB6_S0f6cmJRzqone1AI4Csc55WPp1VrE6cXvv3648130_provenance.
- NP703922.RADZBjqW_lxGJaNjDqXfqFOGH9pE9LtszQJj38A-F5m4I130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP703922.RADZBjqW_lxGJaNjDqXfqFOGH9pE9LtszQJj38A-F5m4I130_provenance.
- NP614249.RAJtBwM5_k4D6DVIJyiM2qjjlid0Jqi70jG82Ji7OvMOY130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614249.RAJtBwM5_k4D6DVIJyiM2qjjlid0Jqi70jG82Ji7OvMOY130_provenance.
- NP614328.RA0rQ1ajI1tOOdNw1n34iUd2gDw-innQy7dGG5D6rbyCo130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614328.RA0rQ1ajI1tOOdNw1n34iUd2gDw-innQy7dGG5D6rbyCo130_provenance.
- NP703921.RAOogpZgQkWdSIEF-Yf2reqTJCEqYp5pPtQcq2v1Hbxdg130_assertion description "[Inhibitors of the tyrosine kinase receptors, such as IGF-1R, c-kit, PDGFR, VEGFR, or the mTOR signaling pathway, proteasome, angiogenesis, and stress response proteins are under clinical evaluation against sarcomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP703921.RAOogpZgQkWdSIEF-Yf2reqTJCEqYp5pPtQcq2v1Hbxdg130_provenance.